Yangbing Zhao

Duke University — United States

Medicine · Health Sciences

47h-index14.1kcitations96works1.32yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

CAR-T cell therapy research(72), Virus-based gene therapy research(33), Immunotherapy and Immune Responses(26), Immune Cell Function and Interaction(20), CRISPR and Genetic Engineering(18)

Publications96 total

A NOVEL MODELING APPROACH TO ELUCIDATE THE ROLE OF AUTOANTIBODIES IN COMPLEMENT ACTIVATION IN SLE
The Journal of Rheumatology·2025Open Access
Balancing Interpretability and Flexibility in Modeling Diagnostic Trajectories with an Embedded Neural Hawkes Process Model
PubMed·2025Open Access
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication
Journal of Clinical Investigation·2024· 4 citedOpen Access
Two cases of severe pulmonary toxicity from highly active mesothelin-directed CAR T cells
Molecular Therapy·2023· 78 citedOpen Access
A Phase I Study of CD19‐targeted 19(T2)28z1xx CAR T Cells in Adult Patients with Relapsed or Refractory Diffuse Large B‐cell Lymphoma
Hematological Oncology·2023· 1 citedOpen Access
Data from Identification of Chimeric Antigen Receptors That Mediate Constitutive or Inducible Proliferation of T Cells
2023Open Access
Data from Affinity-Tuned ErbB2 or EGFR Chimeric Antigen Receptor T Cells Exhibit an Increased Therapeutic Index against Tumors in Mice
2023Open Access
PSMA-targeting TGFβ-insensitive armored CAR T cells in metastatic castration-resistant prostate cancer: a phase 1 trial
Nature Medicine·2022· 456 citedOpen Access
An open, single-center, exploratory clinical trial to evaluate the safety and efficacy of RNA CAR-mesothelin T cells in patients with advanced refractory pancreatic cancer.
Journal of Clinical Oncology·2022
CCR5-edited CD4+ T cells augment HIV-specific immunity to enable post-rebound control of HIV replication
Journal of Clinical Investigation·2021· 93 citedOpen Access
A rational mouse model to detect on-target, off-tumor CAR T cell toxicity
JCI Insight·2020· 91 citedOpen Access
Tim-4 in Health and Disease: Friend or Foe?
Frontiers in Immunology·2020· 44 citedOpen Access
CRISPR-engineered T cells in patients with refractory cancer
Science·2020· 1.4k citedOpen Access
First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma
Blood·2019· 14 cited
iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity
Genome biology·2019· 79 citedOpen Access
Additional file 1: of iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity
Figshare·2019Open Access
Additional file 2: of iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity
Figshare·2019Open Access
Additional file 4: of iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity
2019Open Access
Additional file 3: of iGUIDE: an improved pipeline for analyzing CRISPR cleavage specificity
Figshare·2019Open Access
Abstract IA20: Updates on CAR T Cells
Cancer Immunology Research·2018
page 1 of 5Next →

Frequent Co-authors

Carl H. June(25), Steven A. Rosenberg(15), Xiaojun Liu(14), Zhili Zheng(13), Shuguang Jiang(10), Bruce L. Levine(9), Richard A. Morgan(9), Joseph A. Fraietta(7), Gabriela Plesa(7), Simon F. Lacey(7), Michael Kalos(7), Cyrille J. Cohen(7), J. Joseph Melenhorst(6), Regina M. Young(6), Chongyun Fang(6), Marcela V. Maus(6), Megan M. Davis(5), Anne Chew(5), Steven Μ. Albelda(5), John Scholler(5)